Fluticasone propionate

Generic Name: Fluticasone propionate

Brand Names: Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₁F_₃O_₅S

CAS Number: 80474-14-2

Unique Ingredient Identifier: O2GMZ0LF5W

Background: Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.

Indication: Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.

Associated Conditions: Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis

Associated Therapies: -

Clinical Trials

Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment

Not Applicable

Completed

Conditions: Atopy
Asthma

Interventions: Drug: Placebo
Drug: fluticasone

First Posted Date: 2012-02-23

Last Posted Date: 2016-11-30

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 84

Registration Number: NCT01537133

Locations: 🇺🇸
National Jewish Health, Denver, Colorado, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Duke University School of Medicine, Durham, North Carolina, United States

and more 6 locations

12-Week Study in Adult Subjects With Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone Propionate

First Posted Date: 2012-01-24

Last Posted Date: 2014-12-11

Lead Sponsor: Dey

Target Recruit Count: 629

Registration Number: NCT01516073

Locations: 🇺🇸
Greenville Pharmaceutical research, Inc., Greenville, South Carolina, United States

Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Seretide
Drug: Flixotide
Drug: Flutiform

First Posted Date: 2012-01-18

Last Posted Date: 2018-10-24

Lead Sponsor: Mundipharma Research Limited

Target Recruit Count: 498

Registration Number: NCT01511367

Locations: 🇭🇺
Illés és Ádám Egészségügyi Szolgáltató Bt., Kiskunhalas, Hungary
🇨🇿
Alergologie Skopkova s.r.o, Ostrava-Marianske Hory, Czechia
🇵🇱
Alergo-Med Specjalistyczna Przychodnia Lekarska Sp.z.o.o., Tarnow, Poland

and more 1 locations

Special Drug Use Investigation for ALLERMIST (Long Term)

Completed

Conditions: Rhinitis

Interventions: Drug: Fluticasone

First Posted Date: 2011-08-22

Last Posted Date: 2015-03-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 500

Registration Number: NCT01420822

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Fluticasone propionate
Drug: BI 54903

First Posted Date: 2011-07-19

Last Posted Date: 2022-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT01397201

Locations: 🇺🇸
1248.6.01019 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸
1248.6.01049 Boehringer Ingelheim Investigational Site, Berlin, New Jersey, United States
🇺🇸
1248.6.01040 Boehringer Ingelheim Investigational Site, Pittsburgh, Pennsylvania, United States

and more 38 locations

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: BI 54903
Drug: Placebo
Drug: Fluticasone propionate

First Posted Date: 2011-07-19

Last Posted Date: 2022-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 29

Registration Number: NCT01397162

Locations: 🇺🇸
1248.5.01047 Boehringer Ingelheim Investigational Site, Fountain Valley, California, United States
🇺🇸
1248.5.01042 Boehringer Ingelheim Investigational Site, Sarasota, Florida, United States
🇺🇸
1248.5.01013 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States

and more 38 locations

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Fluticasone propionate
Drug: BI 54903

First Posted Date: 2011-07-18

Last Posted Date: 2022-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 9

Registration Number: NCT01396278

Locations: 🇺🇸
1248.7.01035 Boehringer Ingelheim Investigational Site, Aventura, Florida, United States
🇺🇸
1248.7.01056 Boehringer Ingelheim Investigational Site, Rolla, Missouri, United States
🇺🇸
1248.7.01013 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States

and more 34 locations